Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Aug 5;45(8):182.
doi: 10.1007/s00296-025-05932-1.

Classic lipid profile and lipoprotein(a) in systemic sclerosis: a systematic review and meta-analysis of case-control studies

Christina Mastori-Kourmpani  1 , Anastasios Makris  2 , Evangelos Liberopoulos  3 , Petros P Sfikakis  3 , Aris P Agouridis  4   5
Affiliations
Meta-Analysis

Classic lipid profile and lipoprotein(a) in systemic sclerosis: a systematic review and meta-analysis of case-control studies

Christina Mastori-Kourmpani et al. Rheumatol Int. .

Abstract

Background and aims: Systemic sclerosis (SSc) is a systemic autoimmune disease characterized by fibrosis, vascular abnormalities, and immune dysfunction. Whether patients with SSc exhibit lipid profile abnormalities, which may increase cardiovascular risk, remains uncertain. Our aim was to systematically investigate whether total cholesterol (TCHOL), triglycerides (TRG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and Lipoprotein (a) [Lp(a)] are affected in SSc patients.

Methods: PubMed and Cochrane library databases were systematically searched up to 30 November 2024 for studies reporting on lipid profile (TCHOL, TRG, HDL-C, LDL-C) and Lp(a) in patients with SSc. Qualitative and quantitative syntheses of data from published prospective and retrospective studies was performed.

Results: Literature search identified 27 eligible trials including 2503 participants, of whom 1114 were SSc patients and 1389 were healthy controls (HC). The pooled analysis from 24 studies (1001 SSc patients and 1254 HC) demonstrated that SSc patients had significantly lower HDL-C levels compared with the HC group (MD:- 5.61 mg/dl, 95% CI- 8.22,- 3.00, I2 = 83%). Regarding TRGs, pooled analysis from 24 studies (1016 SSc patients and 1246 HC) showed significantly higher levels in SSc compared with HC (MD: 16.98 mg/dl, 95% CI 8.28, 25.68, I2 = 68%). Similarly, the pooled analysis from 3 studies (131 SSc patients and 206 HC) showed significantly higher Lp(a) levels in SSc compared with HC (MD: 15.66 mg/dl, 95% CI 6.77, 24.55, I2 = 5%). No significant differences were observed in TCHOL (MD: 0.94 mg/dl, 95% CI- 10.23, 12.10, I2 = 93%), and LDL-C (MD:- 6.12 mg/dl, 95% CI- 16.00, 3.77, I2 = 95%) levels between SSc and HC groups.

Conclusions: HDL-C levels are decreased in SSc, contrary to TRG and Lp(a) levels, which are increased. These findings may have implications in assessing cardiovascular risk in patients with SSc.

Trail registry: CRD42024607564.

Keywords: Dyslipidemia; Lipoprotein (a); Lipoproteins; Systemic sclerosis.

PubMed Disclaimer

Conflict of interest statement

Declarations. Editing: Editing was not supported by any agency in the present manuscript. AI usage: No AI software was used in any part of the present manuscript. Competing interests: The authors declare no Competing interests.

Similar articles

See all similar articles

References

    1. Bournia VK, Fragoulis GE, Mitrou P, Mathioudakis K, Tsolakidis A, Konstantonis G, Vourli G, Paraskevis D, Tektonidou MG, Sfikakis PP (2021) All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015–2019. RMD Open 7. https://doi.org/10.1136/rmdopen-2021-001694 - DOI
    1. Bournia VK, Fragoulis GE, Mitrou P, Tsolakidis A, Mathioudakis K, Vassilopoulos D, Tektonidou M, Paraskevis D, Sfikakis PP (2024) Increased prevalence of inflammatory arthritis, systemic lupus erythematosus and systemic sclerosis, during 2020–2023 versus 2016–2019 in a nation-wide cohort study. Rheumatol Int 44:2837–2846. https://doi.org/10.1007/s00296-024-05733-y - DOI - PubMed
    1. Volkmann ER, Andréasson K, Smith V (2023) Systemic sclerosis. Lancet 401:304–318. https://doi.org/10.1016/s0140-6736(22)01692-0 - DOI - PubMed
    1. Makris A, Panagiotopoulos A, Distler O, Sfikakis PP (2024) Systemic sclerosis sine scleroderma: a time of reappraisal. J Rheumatol 51:1060–1068. https://doi.org/10.3899/jrheum.2023-1113 - DOI - PubMed
    1. Cen X, Feng S, Wei S, Yan L, Sun L (2020) Systemic sclerosis and risk of cardiovascular disease: A PRISMA-compliant systemic review and meta-analysis of cohort studies. Med (Baltim) 99:e23009. https://doi.org/10.1097/md.0000000000023009 - DOI

LinkOut - more resources